{"id":2428,"date":"2017-11-08T19:53:00","date_gmt":"2017-11-08T19:53:00","guid":{"rendered":"https:\/\/cdafound.org\/?p=2428"},"modified":"2025-01-15T03:19:43","modified_gmt":"2025-01-15T03:19:43","slug":"hepatitis-c-virus-dynamics-among-intravenous-drug-users-suggest-that-an-annual-treatment-uptake-above-10-would-eliminate-the-disease-by-2030","status":"publish","type":"post","link":"https:\/\/cdafound.org\/fr\/hepatitis-c-virus-dynamics-among-intravenous-drug-users-suggest-that-an-annual-treatment-uptake-above-10-would-eliminate-the-disease-by-2030\/","title":{"rendered":"La dynamique du virus de l&#039;h\u00e9patite C parmi les utilisateurs de drogues intraveineuses sugg\u00e8re qu&#039;un traitement annuel sup\u00e9rieur \u00e0 10% \u00e9liminerait la maladie d&#039;ici 2030"},"content":{"rendered":"<h2 class=\"wp-block-heading\">R\u00e9sum\u00e9<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\"><br>Contexte et objectifs<\/h3>\n\n\n\n<p>En Suisse, la pr\u00e9valence du virus de l\u2019h\u00e9patite C (VHC) parmi les consommateurs de drogues injectables (CDI) est en baisse gr\u00e2ce aux efforts actifs de r\u00e9duction des risques et au vieillissement de la population. Les avanc\u00e9es r\u00e9centes dans le domaine th\u00e9rapeutique du VHC pourraient offrir l\u2019occasion d\u2019orienter le traitement vers les populations \u00e0 haut risque, dans le but de r\u00e9duire la pr\u00e9valence du VHC et de pr\u00e9venir de nouvelles infections.<br>Afin de guider ces efforts, le projet actuel a \u00e9t\u00e9 entrepris avec les objectifs suivants: (1) d\u00e9velopper un mod\u00e8le simple pour estimer le nombre de nouvelles infections par le VHC en utilisant les donn\u00e9es disponibles sur les UDI; (2) examiner l&#039;impact des strat\u00e9gies d&#039;intervention (pr\u00e9vention et traitement) sur les infections nouvelles et totales par le VHC chez les PID.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><br>M\u00e9thodes<\/h3>\n\n\n\n<p>Un mod\u00e8le de transmission dynamique du VHC a \u00e9t\u00e9 utilis\u00e9 pour suivre l&#039;incidence et la pr\u00e9valence du VHC parmi les PID actifs en fonction de leur statut de r\u00e9duction des m\u00e9faits. L&#039;impact relatif du traitement de 1, 5, 10 ou 15% de HCV + PWID avec de nouveaux antiviraux oraux \u00e0 action directe a \u00e9t\u00e9 pris en compte.<\/p>\n\n\n\n<h4 class=\"wp-block-heading\"><br>R\u00e9sultats<\/h4>\n\n\n\n<p>En 2015, on estimait \u00e0 10 160 le nombre de consommateurs actifs de drogues injectables en Suisse, dont plus de 851 TP3T participaient \u00e0 des programmes de r\u00e9duction des risques. Environ 421 TP3T des consommateurs actifs de drogues injectables \u00e9taient ARN-VHC+, avec 55 nouvelles infections vir\u00e9miques survenant chaque ann\u00e9e. D&#039;ici 2030, on s&#039;attend \u00e0 une r\u00e9duction de 601 TP3T de la population de consommateurs de drogues injectables ARN-VHC+. En l&#039;absence de changements de comportement, le nombre d&#039;infections secondaires augmenterait dans tous les sc\u00e9narios de traitement. Avec un traitement de haut niveau, le nombre d&#039;infections secondaires atteindrait un pic puis diminuerait, correspondant \u00e0 l&#039;\u00e9puisement du pool viral. En Suisse, un traitement de 51 TP3T de la population de consommateurs de drogues injectables ARN-VHC+ de 2015 par an entra\u00eenerait une r\u00e9duction de 951 TP3T du nombre total de cas d&#039;ici 2030, tandis qu&#039;un traitement \u2265 101 TP3T entra\u00eenerait une r\u00e9duction de &gt; 991 TP3T.<\/p>\n\n\n\n<h4 class=\"wp-block-heading\"><br>Conclusions<\/h4>\n\n\n\n<p>Un traitement rapide du virus de l&#039;h\u00e9patite C chez les personnes qui s&#039;injectent des drogues est n\u00e9cessaire pour r\u00e9duire la pr\u00e9valence et pr\u00e9venir de nouvelles infections en Suisse.<\/p>\n\n<div class=\"wp-block-buttons is-content-justification-center is-layout-flex wp-block-buttons-is-layout-flex\">\n<div class=\"wp-block-button is-style-outline is-style-outline--1\"><a class=\"wp-block-button__link has-text-color wp-element-button\" href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/29120012\/\" target=\"_blank\" rel=\"noreferrer noopener\">Lire le rapport complet<\/a><\/div>\n<\/div>","protected":false},"excerpt":{"rendered":"<p>Summary Background and Aims In Switzerland, the prevalence of hepatitis C virus (HCV) among people who inject drugs (PWID) has been decreasing owing to active harm reduction efforts and an aging population. Recent advances in HCV therapeutics may provide an opportunity to direct treatment to high-risk populations, with a goal of reducing HCV prevalence and [&hellip;]<\/p>\n","protected":false},"author":24,"featured_media":2463,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[1],"tags":[31,10,16],"publication-author":[913,104,389,103,916,97,912,915,914,106,910,911,93],"class_list":["post-2428","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-uncategorized","tag-elimination","tag-hcv","tag-pwid","publication-author-andri-rauch","publication-author-beat-mullhaupt","publication-author-daniel-lavanchy","publication-author-david-semela","publication-author-franco-negro","publication-author-homie-razavi","publication-author-jan-fehr","publication-author-marcel-stoeckle","publication-author-patrick-schmid","publication-author-philip-bruggmann","publication-author-pierre-deltenre","publication-author-roger-kouyos","publication-author-sarah-blach"],"acf":[],"_links":{"self":[{"href":"https:\/\/cdafound.org\/fr\/wp-json\/wp\/v2\/posts\/2428","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cdafound.org\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cdafound.org\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cdafound.org\/fr\/wp-json\/wp\/v2\/users\/24"}],"replies":[{"embeddable":true,"href":"https:\/\/cdafound.org\/fr\/wp-json\/wp\/v2\/comments?post=2428"}],"version-history":[{"count":6,"href":"https:\/\/cdafound.org\/fr\/wp-json\/wp\/v2\/posts\/2428\/revisions"}],"predecessor-version":[{"id":7547,"href":"https:\/\/cdafound.org\/fr\/wp-json\/wp\/v2\/posts\/2428\/revisions\/7547"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cdafound.org\/fr\/wp-json\/wp\/v2\/media\/2463"}],"wp:attachment":[{"href":"https:\/\/cdafound.org\/fr\/wp-json\/wp\/v2\/media?parent=2428"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cdafound.org\/fr\/wp-json\/wp\/v2\/categories?post=2428"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cdafound.org\/fr\/wp-json\/wp\/v2\/tags?post=2428"},{"taxonomy":"publication-author","embeddable":true,"href":"https:\/\/cdafound.org\/fr\/wp-json\/wp\/v2\/publication-author?post=2428"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}